Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
32.1M
-
Shares change
-
-1.52M
-
Total reported value, excl. options
-
$335M
-
Value change
-
-$7.02M
-
Put/Call ratio
-
2.11
-
Number of buys
-
68
-
Number of sells
-
-53
-
Price
-
$10.43
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2020
155 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2020.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.1M shares
of 49.6M outstanding shares and own 64.73% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.33M shares), STATE STREET CORP (3.37M shares), FRED ALGER MANAGEMENT, LLC (2.47M shares), Camber Capital Management LP (2.4M shares), RENAISSANCE TECHNOLOGIES LLC (1.47M shares), TANG CAPITAL MANAGEMENT LLC (1.37M shares), Palo Alto Investors LP (1.34M shares), ACADIAN ASSET MANAGEMENT LLC (1.27M shares), Sofinnova Investments, Inc. (1.2M shares), and MILLENNIUM MANAGEMENT LLC (1.17M shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.